Equities analysts expect Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to post $2.42 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Portola Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.40 million and the highest estimate coming in at $2.44 million. Portola Pharmaceuticals posted sales of $9.32 million during the same quarter last year, which suggests a negative year over year growth rate of 74%. The firm is scheduled to announce its next earnings report on Monday, November 6th.

On average, analysts expect that Portola Pharmaceuticals will report full year sales of $2.42 million for the current year, with estimates ranging from $13.72 million to $24.44 million. For the next fiscal year, analysts forecast that the firm will report sales of $261.71 million per share, with estimates ranging from $158.00 million to $369.15 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that follow Portola Pharmaceuticals.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.12). Portola Pharmaceuticals had a negative return on equity of 145.12% and a negative net margin of 807.93%. The company had revenue of $3.79 million during the quarter, compared to analysts’ expectations of $4.28 million. During the same quarter in the prior year, the business posted ($1.02) EPS. The company’s revenue for the quarter was down 10.4% compared to the same quarter last year.

A number of analysts recently commented on PTLA shares. Oppenheimer Holdings, Inc. lifted their target price on shares of Portola Pharmaceuticals from $66.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. BidaskClub upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $70.00 price target on the stock in a research note on Tuesday, July 18th. Credit Suisse Group set a $70.00 price target on shares of Portola Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, August 10th. They noted that the move was a valuation call. Finally, Cowen and Company raised their price target on shares of Portola Pharmaceuticals from $45.00 to $70.00 and gave the stock an “outperform” rating in a report on Monday, June 26th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $63.77.

TRADEMARK VIOLATION NOTICE: “$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (PTLA) This Quarter” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/2-42-million-in-sales-expected-for-portola-pharmaceuticals-inc-ptla-this-quarter-2.html.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down 0.83% during midday trading on Wednesday, reaching $53.72. 560,417 shares of the company’s stock were exchanged. The firm’s market cap is $3.10 billion. The stock’s 50-day moving average is $56.05 and its 200 day moving average is $48.69. Portola Pharmaceuticals has a one year low of $15.68 and a one year high of $67.10.

In other news, EVP Tao Fu sold 5,812 shares of the company’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $65.00, for a total value of $377,780.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Mardi Dier sold 23,350 shares of the company’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $60.00, for a total value of $1,401,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,162 shares of company stock valued at $2,428,780. Company insiders own 4.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Hanseatic Management Services Inc. lifted its holdings in Portola Pharmaceuticals by 0.3% in the second quarter. Hanseatic Management Services Inc. now owns 22,800 shares of the biopharmaceutical company’s stock valued at $1,281,000 after acquiring an additional 70 shares during the period. IFP Advisors Inc boosted its position in Portola Pharmaceuticals by 7.7% in the 2nd quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 170 shares in the last quarter. Principal Financial Group Inc. boosted its position in Portola Pharmaceuticals by 0.3% in the 1st quarter. Principal Financial Group Inc. now owns 62,322 shares of the biopharmaceutical company’s stock worth $2,442,000 after purchasing an additional 202 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Portola Pharmaceuticals by 14.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 258 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in Portola Pharmaceuticals by 1.6% in the 1st quarter. Legal & General Group Plc now owns 18,364 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 290 shares in the last quarter. Institutional investors own 85.02% of the company’s stock.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Get a free copy of the Zacks research report on Portola Pharmaceuticals (PTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.